Visionary’s portfolio company Tear Film Innovations’ iLux spotlighted in an Ophthalmology Management Article about Treatment of Meibomian gland disfunction (MGD).
Visionary Ventures
Life sciences venture capital fund investing in ophthalmology and medical aesthetics.
